<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271020</url>
  </required_header>
  <id_info>
    <org_study_id>CP00009</org_study_id>
    <nct_id>NCT04271020</nct_id>
  </id_info>
  <brief_title>Urodynamic Feasibility Study Utilizing the UroLift® System</brief_title>
  <acronym>UDS</acronym>
  <official_title>Urodynamic Feasibility Study (UDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoTract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoTract, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      UDS evaluates the impact of Prostatic Urethral Lift (PUL) as measured by pressure flow,
      urodynamic testing (UDS) and an optional UroCuff Testing, an alternative urodynamic test. In
      addition, standard BPH measures such as symptoms, qualify of life, uroflowmetry, and post
      void residual will be evaluated at screening and at the follow-up visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Actual">November 27, 2019</completion_date>
  <primary_completion_date type="Actual">April 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qmax Assessed Using Urodynamic Testing (Cystometry)</measure>
    <time_frame>3 Month</time_frame>
    <description>Qmax is the the maximum urinary flow rate measured in ml/s.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pdet at Qmax Assessed Using Urodynamic Testing (Cystometry)</measure>
    <time_frame>3 Month</time_frame>
    <description>Pdet is detrusor pressure at Qmax (maximum urinary flow rate) measured in cm H2O.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pdetmax Assessed Using Urodynamic Testing (Cystometry)</measure>
    <time_frame>3 Month</time_frame>
    <description>Pdetmax is the maximum void pressure measured in cm H2O.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>UroLift</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UroLift</intervention_name>
    <description>The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).
During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.</description>
    <arm_group_label>UroLift</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male gender

          -  Diagnosis of symptomatic BPH

          -  Age ≥ 45 years

          -  International Prostate Symptom Score (IPSS) ≥ 13

          -  Peak urine flow rate ≤ 12 ml/sec, voided volume ≥ 125 ml

          -  Prostate volume ≤ 80 cc per ultrasound

        Exclusion Criteria:

          -  Current urinary retention

          -  Post void residual (PVR) urine &gt; 250 ml

          -  Have an obstructive or protruding median lobe of the prostate

          -  Active urinary tract infection at time of treatment

          -  Current gross hematuria

          -  Previous BPH surgical procedure

          -  Previous pelvic surgery or irradiation

          -  History of neurogenic or atonic bladder

          -  Stress urinary incontinence

          -  Biopsy of the prostate within the past 6 weeks

          -  Life expectancy estimated to be less than 1 year

          -  History of prostate or bladder cancer

          -  Elevated Prostate-Specific Antigen (PSA) without ruling out prostate cancer

          -  History of compromised renal function or upper tract disease

          -  Known coagulopathies or subject on anticoagulants or antiplatelets other than aspirin
             ≤ 100 mg (unless antiplatelets are withheld minimum 3 days prior to procedure)

          -  Use of the following medications pre-screening (uroflow, questionnaires):

               -  Within 4 months of baseline assessment: estrogen, any drug producing androgen
                  suppression, or anabolic steroids

               -  Within 3 months of baseline assessment: 5-alpha-reductase inhibitors

               -  Within 2 weeks of baseline assessment: alpha-blockers, gonadotropin-releasing
                  hormonal analogs, anticholinergics or cholinergic medication or phenylephrine,
                  pseudoephedrine, or imipramine medications

               -  Within 1 week of baseline assessment, unless documented on stable dose for ≥ 6
                  months: beta blockers, antidepressants, anticonvulsants, and antispasmodics

          -  Cystolithiasis within the prior 3 months

          -  History of co-morbidities that would affect having an elective urological procedure
             including: prostatitis, conditions that preclude the insertion of the UroLift System.

          -  Other co-morbidities that could impact the study results such as:

          -  Severe cardiac arrhythmias uncontrolled by medications or pacemaker

          -  Congestive heart failure New York Heart Assocation (NYHA) III or IV

          -  History of uncontrolled diabetes mellitus

          -  Significant respiratory disease in which hospitalization may be required

          -  Known immunosuppression (i.e. AIDS, post-transplant, undergoing chemotherapy)

          -  A known allergy to nickel, titanium, or stainless steel

          -  Unable or unwilling to complete all required questionnaires and follow up assessments

          -  Unable or unwilling to sign informed consent form

          -  Currently enrolled in any other investigational clinical research trial that has not
             completed the primary endpoint.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients must be male. The study is evaluation the population of men diagnosed with benign prostatic hyperplasia.</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Mazzarella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midtown Urology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midtown Urology Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <results_first_submitted>April 23, 2020</results_first_submitted>
  <results_first_submitted_qc>April 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2020</results_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT04271020/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>UroLift</title>
          <description>UroLift: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).
During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>UroLift</title>
          <description>UroLift: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).
During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.44" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Qmax</title>
          <units>mL/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pdet @ Qmax</title>
          <population>Unable to interpret data from 3 subjects collected at baseline.</population>
          <units>cmH20</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.9" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pdetmax</title>
          <population>Unable to interpret data from 3 subjects collected at baseline.</population>
          <units>cmH20</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.9" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Qmax Assessed Using Urodynamic Testing (Cystometry)</title>
        <description>Qmax is the the maximum urinary flow rate measured in ml/s.</description>
        <time_frame>3 Month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UroLift</title>
            <description>UroLift: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).
During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.</description>
          </group>
        </group_list>
        <measure>
          <title>Qmax Assessed Using Urodynamic Testing (Cystometry)</title>
          <description>Qmax is the the maximum urinary flow rate measured in ml/s.</description>
          <units>mL/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pdet at Qmax Assessed Using Urodynamic Testing (Cystometry)</title>
        <description>Pdet is detrusor pressure at Qmax (maximum urinary flow rate) measured in cm H2O.</description>
        <time_frame>3 Month</time_frame>
        <population>Overall number of participants analyzed is fewer than the total number of participants (12) and number of participants analyzed at baseline (8) because unable to interpret data collected at 3 months.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift</title>
            <description>UroLift: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).
During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.</description>
          </group>
        </group_list>
        <measure>
          <title>Pdet at Qmax Assessed Using Urodynamic Testing (Cystometry)</title>
          <description>Pdet is detrusor pressure at Qmax (maximum urinary flow rate) measured in cm H2O.</description>
          <population>Overall number of participants analyzed is fewer than the total number of participants (12) and number of participants analyzed at baseline (8) because unable to interpret data collected at 3 months.</population>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pdetmax Assessed Using Urodynamic Testing (Cystometry)</title>
        <description>Pdetmax is the maximum void pressure measured in cm H2O.</description>
        <time_frame>3 Month</time_frame>
        <population>Overall number of participants analyzed is fewer than the total number of participants (12) and number of participants analyzed at baseline (8) because unable to interpret data collected at 3 months.</population>
        <group_list>
          <group group_id="O1">
            <title>UroLift</title>
            <description>UroLift: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).
During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.</description>
          </group>
        </group_list>
        <measure>
          <title>Pdetmax Assessed Using Urodynamic Testing (Cystometry)</title>
          <description>Pdetmax is the maximum void pressure measured in cm H2O.</description>
          <population>Overall number of participants analyzed is fewer than the total number of participants (12) and number of participants analyzed at baseline (8) because unable to interpret data collected at 3 months.</population>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.5" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 1 day, until the AE was resolved, during the 1-3 Day Visit after release from procedure time frame.</time_frame>
      <desc>Not applicable - Adverse event and/or serious adverse event definition used in this study is the same as defined on clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>UroLift</title>
          <description>UroLift: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).
During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI agree not to make any Publications of Study results until completion of the Study and Publication of the results in a peer-reviewed journal by Sponsor. Thereafter, PI may publish their individual site experience. Should a manuscript not be submitted by Sponsor within 12 months of study closure, PI may publish study results. PI shall provide Sponsor 30 days prior notice of publication submission date and text of proposed Publication for review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emily Friedland, Director, Global Clinical Affairs</name_or_title>
      <organization>NeoTract, Inc.</organization>
      <phone>1-610-331-7299</phone>
      <email>emily.friedland@teleflex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

